What they do:
Fermentation-derived natural products to solve health problems
Quick facts:
HQ: San Diego, CA, United States
Top Biotech Startups in San Diego
This list has 14 startups and was last updated on Oct 15, 2026. Largest teams: CB Therapeutics, Persephone Biosciences, and Origami Therapeutics, Inc. Latest round: Anvion Bio raised $100K (Oct 7, 2026).
14 startups
What they do:
We are using the gut microbiome to end cancer.
Quick facts:
HQ: San Diego, CA, United States
What they do:
Oral drugs to halt neurodegeneration
Quick facts:
HQ: San Diego, CA, United States
What they do:
Bioengineered kidneys for patients with kidney failure
Quick facts:
HQ: San Diego, CA, United States
What they do:
High quality mRNA for therapeutic application
Quick facts:
HQ: San Diego, CA, United States
Quick facts:
HQ: San Diego, CA, United States
Funding:
$27.8M · Equity · Apr 2026
Quick facts:
HQ: San Diego, CA, United States
Funding:
$26M · Options · Jan 2026
Quick facts:
HQ: San Diego, CA, United States
Funding:
$19.5M · Equity · Jun 2026
Quick facts:
HQ: San Diego, CA, United States
Incorporated: 2022
Funding:
$11.4M · Equity · Sep 2026
Quick facts:
HQ: San Diego, CA, United States
Funding:
$8.97M · Options · Oct 2026
Quick facts:
HQ: San Diego, CA, United States
Funding:
$6.68M · Equity · Mar 2026
Quick facts:
HQ: San Diego, CA, United States
Incorporated: 2021
Funding:
$4.12M · Equity · Jan 2026
Quick facts:
HQ: San Diego, CA, United States
Funding:
$1.3M · Jan 2026
Quick facts:
HQ: San Diego, CA, United States
Incorporated: 2026
Funding:
$100K · Equity · Oct 2026
Questions and answers
How many startups are on this list?
There are 14 startups on this list, last updated on Oct 15, 2026.
Which of them are hiring?
None of them shows open roles right now.
Which of them have the largest teams?
By team size: CB Therapeutics (18 employees), Persephone Biosciences (6 employees), and Origami Therapeutics, Inc. (4 employees).
Which of them raised money recently?
Latest rounds: Anvion Bio — $100K Equity (Oct 2026), Rakuten Medical — $8.97M Options (Oct 2026), and Vetmab Biosciences — $11.4M Equity (Sep 2026).